Cancer du poumon à petites cellules : prise en charge et nouveautés [Small-cell lung cancer: management and novelties]
Fiche du document
27 mai 2020
- doi: 10.53738/REVMED.2020.16.695.1079
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.695.1079
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32462835
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3F2FC3093CB55
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
LungCiter ce document
K. Abdelhamid et al., « Cancer du poumon à petites cellules : prise en charge et nouveautés [Small-cell lung cancer: management and novelties] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.695.1079
Métriques
Partage / Export
Résumé
Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In the majority of cases, patients have metastatic disease at diagnosis despite the new screening method by low-dose CT-scan. The high throughput sequencing has deepened our understanding of its biology. While the treatment of localized disease has changed little, the arrival of immune checkpoint inhibitors have revolutionized the management of extensive disease. At the same time, new strategies involving certain potential genetic targets are being analyzed on a large scale that could become valuable therapeutic alternatives in the future. Radiation therapy remains a very useful therapeutic modality in all stages of the disease. This article aims to review the epidemiology, molecular pathology, management and innovative therapies in small-cell lung cancer.